O	0	6	Double
O	6	7	-
O	7	12	Blind
O	12	13	,
O	14	24	Randomized
O	25	30	Trial
O	31	33	of
O	34	45	Alternative
B-intervention	46	55	Letrozole
O	56	62	Dosing
O	63	71	Regimens
O	72	74	in
O	75	89	Postmenopausal
O	90	95	Women
O	96	100	with
O	101	110	Increased
O	111	117	Breast
O	118	124	Cancer
O	125	129	Risk
O	129	130	.

O	131	140	Aromatase
O	141	151	inhibitors
O	152	153	(
O	153	155	AI
O	155	156	)
O	157	167	profoundly
O	168	176	suppress
O	177	185	estrogen
O	186	192	levels
O	193	195	in
O	196	210	postmenopausal
O	211	216	women
O	217	220	and
O	221	224	are
O	225	234	effective
O	235	237	in
O	238	244	breast
O	245	251	cancer
O	252	262	prevention
O	263	268	among
O	269	273	high
O	273	274	-
O	274	278	risk
O	279	293	postmenopausal
O	294	299	women
O	299	300	.

O	301	314	Unfortunately
O	314	315	,
O	316	318	AI
O	319	328	treatment
O	329	331	is
O	332	342	associated
O	343	347	with
O	348	359	undesirable
O	360	364	side
O	365	372	effects
O	373	377	that
O	378	383	limit
O	384	391	patient
O	392	402	acceptance
O	403	406	for
O	407	414	primary
O	415	425	prevention
O	426	428	of
O	429	435	breast
O	436	442	cancer
O	442	443	.

O	444	445	A
O	446	452	double
O	452	453	-
O	453	458	blind
O	458	459	,
O	460	470	randomized
O	471	476	trial
O	477	480	was
O	481	490	conducted
O	491	493	to
O	494	503	determine
O	504	511	whether
O	512	515	low
O	516	519	and
O	520	532	intermittent
O	533	538	doses
O	539	541	of
O	542	551	letrozole
O	552	555	can
O	556	563	achieve
O	564	573	effective
O	574	582	estrogen
O	583	594	suppression
O	595	599	with
O	600	601	a
O	602	606	more
O	607	616	favorable
O	617	621	side
O	621	622	-
O	622	628	effect
O	629	636	profile
O	636	637	.

O	638	645	Overall
O	645	646	,
B-total-participants	647	650	112
B-eligibility	651	665	postmenopausal
I-eligibility	666	671	women
I-eligibility	672	674	at
I-eligibility	675	684	increased
I-eligibility	685	689	risk
I-eligibility	690	693	for
I-eligibility	694	700	breast
I-eligibility	701	707	cancer
O	708	712	were
O	713	723	randomized
O	724	726	to
O	727	734	receive
O	735	744	letrozole
O	745	747	at
O	748	749	2
O	749	750	.
O	750	751	5
O	752	754	mg
O	755	759	once
O	760	765	daily
O	766	767	(
O	767	769	QD
O	769	770	,
B-control	771	779	standard
I-control	780	784	dose
I-control	785	788	arm
O	788	789	)
O	789	790	,
O	791	792	2
O	792	793	.
O	793	794	5
O	795	797	mg
O	798	803	every
O	804	810	Monday
O	810	811	,
O	812	821	Wednesday
O	821	822	,
O	823	826	and
O	827	833	Friday
O	834	835	(
O	835	836	Q
O	836	837	-
O	837	840	MWF
O	840	841	)
O	841	842	,
O	843	844	1
O	844	845	.
O	845	846	0
O	847	849	mg
O	850	851	Q
O	851	852	-
O	852	855	MWF
O	855	856	,
O	857	859	or
O	860	861	0
O	861	862	.
O	862	864	25
O	865	867	mg
O	868	869	Q
O	869	870	-
O	870	873	MWF
O	874	877	for
O	878	880	24
O	881	886	weeks
O	886	887	.

O	888	895	Primary
O	896	904	endpoint
O	905	908	was
B-outcome-Measure	909	920	suppression
I-outcome-Measure	921	923	in
I-outcome-Measure	924	929	serum
I-outcome-Measure	930	939	estradiol
I-outcome-Measure	940	946	levels
O	947	949	at
O	950	953	the
O	954	957	end
O	958	960	of
O	961	970	letrozole
O	971	983	intervention
O	983	984	.

O	985	994	Secondary
O	995	1004	endpoints
O	1005	1013	included
B-outcome-Measure	1014	1021	changes
I-outcome-Measure	1022	1024	in
I-outcome-Measure	1025	1030	serum
I-outcome-Measure	1031	1038	estrone
O	1038	1039	,
B-outcome-Measure	1040	1052	testosterone
O	1052	1053	,
B-outcome-Measure	1054	1055	C
I-outcome-Measure	1055	1056	-
I-outcome-Measure	1056	1067	telopeptide
I-outcome-Measure	1068	1069	(
I-outcome-Measure	1069	1075	marker
I-outcome-Measure	1076	1078	of
I-outcome-Measure	1079	1083	bone
I-outcome-Measure	1084	1094	resorption
I-outcome-Measure	1094	1095	)
O	1095	1096	,
B-outcome-Measure	1097	1102	lipid
I-outcome-Measure	1103	1110	profile
O	1110	1111	,
O	1112	1115	and
B-outcome-Measure	1116	1123	quality
I-outcome-Measure	1123	1124	-
I-outcome-Measure	1124	1126	of
I-outcome-Measure	1126	1127	-
I-outcome-Measure	1127	1131	life
I-outcome-Measure	1132	1140	measures
I-outcome-Measure	1141	1142	(
I-outcome-Measure	1142	1145	QoL
I-outcome-Measure	1145	1146	)
O	1147	1156	following
O	1157	1166	treatment
O	1166	1167	.

O	1168	1179	Significant
B-outcome	1180	1188	estrogen
I-outcome	1189	1200	suppression
O	1201	1204	was
O	1205	1213	observed
O	1214	1216	in
O	1217	1220	all
O	1221	1225	dose
O	1226	1230	arms
O	1231	1235	with
O	1236	1238	an
O	1239	1246	average
O	1247	1249	of
O	1250	1252	75
O	1252	1253	%
O	1254	1256	to
O	1257	1259	78
O	1259	1260	%
O	1261	1264	and
O	1265	1267	86
O	1267	1268	%
O	1269	1271	to
O	1272	1274	93
O	1274	1275	%
B-outcome	1276	1285	reduction
I-outcome	1286	1288	in
I-outcome	1289	1294	serum
I-outcome	1295	1304	estradiol
I-outcome	1305	1308	and
I-outcome	1309	1316	estrone
I-outcome	1317	1323	levels
O	1323	1324	,
O	1325	1337	respectively
O	1337	1338	.

O	1339	1344	There
O	1345	1349	were
O	1350	1352	no
O	1353	1364	differences
O	1365	1370	among
O	1371	1375	dose
O	1376	1380	arms
O	1381	1385	with
O	1386	1393	respect
O	1394	1396	to
B-outcome	1397	1404	changes
I-outcome	1405	1407	in
I-outcome	1408	1409	C
I-outcome	1409	1410	-
I-outcome	1410	1421	telopeptide
I-outcome	1422	1428	levels
O	1428	1429	,
B-outcome	1430	1435	lipid
I-outcome	1436	1443	profile
O	1443	1444	,
B-outcome	1445	1452	adverse
I-outcome	1453	1459	events
I-outcome	1460	1461	(
I-outcome	1461	1463	AE
I-outcome	1463	1464	)
O	1464	1465	,
O	1466	1468	or
B-outcome	1469	1472	QoL
I-outcome	1473	1481	measures
O	1481	1482	.

O	1483	1485	We
O	1486	1494	conclude
O	1495	1499	that
O	1500	1503	low
O	1504	1507	and
O	1508	1520	intermittent
O	1521	1526	doses
O	1527	1529	of
O	1530	1539	letrozole
O	1540	1543	are
O	1544	1547	not
O	1548	1556	inferior
O	1557	1559	to
O	1560	1568	standard
O	1569	1573	dose
O	1574	1576	in
O	1577	1585	estrogen
O	1586	1597	suppression
O	1598	1601	and
O	1602	1610	resulted
O	1611	1613	in
O	1614	1615	a
O	1616	1623	similar
O	1624	1628	side
O	1628	1629	-
O	1629	1635	effect
O	1636	1643	profile
O	1644	1652	compared
O	1653	1657	with
O	1658	1666	standard
O	1667	1671	dose
O	1671	1672	.

O	1673	1680	Further
O	1681	1688	studies
O	1689	1692	are
O	1693	1699	needed
O	1700	1702	to
O	1703	1712	determine
O	1713	1716	the
O	1717	1728	feasibility
O	1729	1731	of
O	1732	1741	selecting
O	1742	1744	an
O	1745	1754	effective
O	1755	1757	AI
O	1758	1764	dosing
O	1765	1773	schedule
O	1774	1778	with
O	1779	1785	better
O	1786	1798	tolerability
O	1798	1799	.
